Drolet Robert E, Behrouz Bahareh, Lookingland Keith J, Goudreau John L
The Neuroscience Program, Michigan State University, B-436 Life Sciences Building, East Lansing, MI 48824, USA.
Neurotoxicology. 2004 Sep;25(5):761-9. doi: 10.1016/j.neuro.2004.05.002.
The functional role of alpha-synuclein in the pathogenesis of Parkinson's disease (PD) is not fully understood. Systemic exposure of alpha-synuclein-deficient mice to neurotoxins provides a direct approach to evaluate how alpha-synuclein may mediate cell death in a common murine model of PD. To this end, wild-type and homozygous alpha-synuclein knock-out mice were treated with sub-chronic and prolonged, chronic exposure to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). In the sub-chronic model, wild-type and alpha-synuclein knock-out mice were treated for five consecutive days with MPTP (1-25 mg/kg, s.c.) or vehicle, and sacrificed 3 days following the last injection. The prolonged, chronic model consisted of two injections of MPTP (1-20 mg/kg, s.c.) per week for 5 weeks, with co-administration of probenecid (250 mg/kg, i.p.), and animals were sacrificed 3 weeks following the last injection. Sub-chronic administration of MPTP caused a dramatic, dose-dependent decrease in striatal dopamine (DA) concentrations, while an attenuated response was observed in alpha-synuclein knock-out mice. Similarly, prolonged, chronic administration of MPTP produced a dose-dependent decrease in striatal DA concentrations, and a corresponding loss of striatal vesicular monoamine transporter (VMAT-2) protein in wild-type mice. However, mice lacking alpha-synuclein had an attenuated loss of striatal DA concentrations, while no loss of striatal VMAT-2 protein was observed. Both sub-chronic and prolonged, chronic administration of MPTP caused an increase in the 3,4-dihydroxyphenylacetic acid (DOPAC) to DA ratio in wild-type mice, but not in mice lacking alpha-synuclein. Despite attenuated toxicity, elevated lactate concentrations were observed in alpha-synuclein knock-out mice following prolonged, chronic MPTP administration. The results of this study provide evidence that alpha-synuclein null mice have an attenuated response to the toxic effects of MPTP exposure, even over prolonged periods of time and that the biochemical sequela of a protracted insult to nigrostriatal DA neurons are distinct between mice with and without alpha-synuclein expression.
α-突触核蛋白在帕金森病(PD)发病机制中的功能作用尚未完全明确。使缺乏α-突触核蛋白的小鼠全身暴露于神经毒素,为评估α-突触核蛋白在常见的PD小鼠模型中如何介导细胞死亡提供了一种直接方法。为此,野生型和纯合α-突触核蛋白基因敲除小鼠接受亚慢性和长期慢性暴露于1-甲基-4-苯基-1,2,3,6-四氢吡啶(MPTP)。在亚慢性模型中,野生型和α-突触核蛋白基因敲除小鼠连续5天接受MPTP(1-25mg/kg,皮下注射)或溶剂处理,并在最后一次注射后3天处死。长期慢性模型包括每周两次注射MPTP(1-20mg/kg,皮下注射),共5周,同时腹腔注射丙磺舒(250mg/kg),动物在最后一次注射后3周处死。亚慢性给予MPTP导致纹状体多巴胺(DA)浓度显著的剂量依赖性降低,而在α-突触核蛋白基因敲除小鼠中观察到反应减弱。同样,长期慢性给予MPTP导致野生型小鼠纹状体DA浓度剂量依赖性降低以及纹状体囊泡单胺转运体(VMAT-2)蛋白相应减少。然而,缺乏α-突触核蛋白的小鼠纹状体DA浓度降低减弱,同时未观察到纹状体VMAT-2蛋白减少。亚慢性和长期慢性给予MPTP均导致野生型小鼠中3,4-二羟基苯乙酸(DOPAC)与DA的比值升高,但在缺乏α-突触核蛋白的小鼠中未出现这种情况。尽管毒性减弱,但在长期慢性给予MPTP后,α-突触核蛋白基因敲除小鼠中观察到乳酸浓度升高。本研究结果表明,α-突触核蛋白基因敲除小鼠对MPTP暴露的毒性作用反应减弱,即使在长时间暴露情况下也是如此,并且在有和没有α-突触核蛋白表达的小鼠中,对黑质纹状体DA神经元长期损伤的生化后遗症是不同的。